MX2009000333A - Pirrilopirimidinas para composiciones farmaceuticas. - Google Patents
Pirrilopirimidinas para composiciones farmaceuticas.Info
- Publication number
- MX2009000333A MX2009000333A MX2009000333A MX2009000333A MX2009000333A MX 2009000333 A MX2009000333 A MX 2009000333A MX 2009000333 A MX2009000333 A MX 2009000333A MX 2009000333 A MX2009000333 A MX 2009000333A MX 2009000333 A MX2009000333 A MX 2009000333A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- pyrrolopyrimidines
- pyrrolopyrimidine compounds
- relates
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
La presente invención se refiere a nuevos compuestos de pirrolopirimidina y a composiciones farmacéuticas que comprenden dichos compuestos de pirrolopirimidina. Además, la presente invención se refiere al uso de los compuestos de pirrolopirimidina de la invención para la producción de composiciones farmacéuticas para la profilaxis y/o el tratamiento de enfermedades que pueden verse influenciadas por la inhibición de la actividad quinasa de Mnk1 y/o Mnk2 (Mnk2a o Mnk2b) y/o de variantes adicionales de las mismas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06014297A EP1889847A1 (en) | 2006-07-10 | 2006-07-10 | Pyrrolopyrimidines for pharmaceutical compositions |
PCT/EP2007/006109 WO2008006547A2 (en) | 2006-07-10 | 2007-07-10 | Pyrrolopyrimidines for pharmaceutical compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009000333A true MX2009000333A (es) | 2009-03-13 |
Family
ID=37496429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009000333A MX2009000333A (es) | 2006-07-10 | 2007-07-10 | Pirrilopirimidinas para composiciones farmaceuticas. |
Country Status (16)
Country | Link |
---|---|
US (1) | US8697713B2 (es) |
EP (2) | EP1889847A1 (es) |
JP (1) | JP5331951B2 (es) |
KR (1) | KR20090039757A (es) |
CN (1) | CN101511837A (es) |
AT (1) | ATE526331T1 (es) |
AU (1) | AU2007271928A1 (es) |
BR (1) | BRPI0712882A2 (es) |
CA (1) | CA2690277A1 (es) |
CO (1) | CO6150162A2 (es) |
EA (1) | EA200900136A1 (es) |
IL (1) | IL196391A0 (es) |
MX (1) | MX2009000333A (es) |
NO (1) | NO20090029L (es) |
WO (1) | WO2008006547A2 (es) |
ZA (1) | ZA200810785B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5302883B2 (ja) | 2006-04-07 | 2013-10-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のmnk1/mnk2阻害活性を有するチエノピリミジン |
EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
US8946239B2 (en) * | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
UY32072A (es) | 2008-08-26 | 2010-03-26 | Boehringer Ingelheim Int | Tienopirimidinas para composiciones farmacéuticas |
US8853193B2 (en) * | 2010-02-26 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
WO2011104338A1 (en) | 2010-02-26 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
EA201201191A1 (ru) | 2010-02-26 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций |
KR20140049961A (ko) * | 2010-11-29 | 2014-04-28 | 갈레온 파마슈티칼스, 인코포레이티드 | 호흡 조절 장애 또는 질병의 치료를 위한 호흡 자극제로서의 신규 화합물 |
US20120295911A1 (en) | 2010-11-29 | 2012-11-22 | Galleon Pharmaceuticals, Inc. | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
KR101286743B1 (ko) * | 2011-02-18 | 2013-07-15 | 충남대학교산학협력단 | 페노피브레이트를 함유하는 패혈증 예방용 약학 조성물 |
ES2650915T3 (es) * | 2011-12-12 | 2018-01-23 | Bayer Intellectual Property Gmbh | Imidazopiridazinas amino-sustituidas |
CA2873971A1 (en) * | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyrimidines |
WO2014025842A1 (en) * | 2012-08-07 | 2014-02-13 | Albert Einstein College Of Medicine Of Yeshiva University | Treatment of helicobacter pylori infections |
WO2014048894A1 (en) | 2012-09-26 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders |
WO2014048869A1 (en) | 2012-09-26 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases |
JP6306035B2 (ja) * | 2012-11-09 | 2018-04-04 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングEvotec International GmbH | 医薬組成物のためのスルホキシミン置換キナゾリン |
EP2951175B1 (en) * | 2013-02-01 | 2017-10-04 | Bayer Pharma Aktiengesellschaft | Substituted pyrazolopyrimidinylamino-indazoles |
WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
AU2014301295C1 (en) * | 2013-06-28 | 2018-03-15 | Evotec International Gmbh | Sulfoximine substituted quinazolines and their use as MNK1 and/or MNK2 kinase inhibitors |
KR20160030239A (ko) * | 2013-07-08 | 2016-03-16 | 바이엘 파마 악티엔게젤샤프트 | 치환된 피라졸로-피리딘아민 |
WO2015091156A1 (en) * | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
CA2944103A1 (en) * | 2014-05-07 | 2015-11-12 | Evotec International Gmbh | Sulfoximine substituted quinazolines for pharmaceutical compositions |
TWI713455B (zh) * | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | MnK抑制劑及其相關方法 |
CN104225597A (zh) * | 2014-09-29 | 2014-12-24 | 武汉大学 | Mapk信号整合激酶1在治疗动脉粥样硬化中的功能和应用 |
WO2016115434A1 (en) | 2015-01-16 | 2016-07-21 | The General Hospital Corporation | Compounds for improving mrna splicing |
US10702526B2 (en) | 2015-04-20 | 2020-07-07 | Effector Therapeutics Inc. | Inhibitors of immune checkpoint modulators and related methods |
AU2016301188A1 (en) | 2015-08-06 | 2018-02-15 | Chimerix, Inc. | Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents |
MX2018005203A (es) | 2015-10-29 | 2018-07-06 | Effector Therapeutics Inc | Compuestos de pirrolo-, pirazolo-, imidazo-pirimidina y pirrolo-, pirazolo-, imidazo-piridina que inhiben cinasas 1 y 2 de interaccion con proteina cinasas activadas por mitogenos (mnk1 y mnk2). |
US10112955B2 (en) * | 2015-10-29 | 2018-10-30 | Effector Therapeutics, Inc. | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 |
US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
GB201520500D0 (en) * | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
GB201520499D0 (en) | 2015-11-20 | 2016-01-06 | Medical Res Council Technology | Compounds |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
WO2017117052A1 (en) | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
US20190117657A1 (en) * | 2016-03-31 | 2019-04-25 | South Australian Health And Medical Research Institute Limited | Method of inhibiting high fat diet-related conditions |
GB2550977B (en) | 2016-05-31 | 2020-07-22 | Cirrus Logic Int Semiconductor Ltd | Monitoring of devices |
JP2019530650A (ja) | 2016-08-24 | 2019-10-24 | アークル インコーポレイテッド | アミノ−ピロロピリミジノン化合物およびその使用方法 |
EA201991894A1 (ru) | 2017-02-14 | 2020-02-05 | Эффектор Терапьютикс, Инк. | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ |
CN109020957B (zh) * | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
US11111264B2 (en) | 2017-09-21 | 2021-09-07 | Chimerix, Inc. | Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof |
US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
KR20210102211A (ko) | 2018-10-24 | 2021-08-19 | 이펙터 테라퓨틱스, 인크. | Mnk 억제제의 결정질 형태 |
CN110483527A (zh) * | 2019-09-09 | 2019-11-22 | 陕西科技大学 | 一种4-氯吡咯[2,3-d]嘧啶取代化合物及其合成方法 |
CA3151199A1 (en) * | 2019-09-19 | 2021-03-25 | New York Society For The Relief Of The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH408945A (de) | 1956-02-10 | 1966-03-15 | Ciba Geigy | Verfahren zur Herstellung von heterocyclischen Verbindungen |
DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
DD248593A1 (de) | 1985-01-11 | 1987-08-12 | Univ Halle Wittenberg | Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern |
DE4008726A1 (de) | 1990-03-19 | 1991-09-26 | Basf Ag | Thieno(2,3-d)pyrimidinderivate |
CA2039411A1 (en) | 1990-03-30 | 1991-10-01 | Ronnie Gerald Edie | Thienopyrimidine derivatives |
TW370529B (en) | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
EP0682027B1 (de) * | 1994-05-03 | 1997-10-15 | Novartis AG | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases |
US6395733B1 (en) * | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
WO1996040142A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
CN1280580A (zh) | 1997-11-11 | 2001-01-17 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
US20030162795A1 (en) * | 1998-10-22 | 2003-08-28 | Pfizer Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
GB9906566D0 (en) * | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
US6643277B2 (en) | 2000-06-29 | 2003-11-04 | Harris Broadband Wireless Access, Inc. | Frequency re-use for point to multipoint applications |
MXPA03009925A (es) | 2001-04-30 | 2004-06-30 | Bayer Pharmaceuticals Corp | Nuevas tiofeno [2,3-d]pirimidinas 4-amino-5,6-sustituidas. |
SE0102147D0 (sv) | 2001-06-18 | 2001-06-18 | Pharmacia Ab | New methods |
DE60238929D1 (de) | 2001-10-29 | 2011-02-24 | Boehringer Ingelheim Int | Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind |
AU2003274652A1 (en) | 2002-10-23 | 2004-05-13 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
US20050012622A1 (en) | 2003-05-19 | 2005-01-20 | Sutton William R. | Monitoring and control of sleep cycles |
CA2527496C (en) | 2003-05-28 | 2012-08-14 | Francesco Bondavalli | 4-substituted derivatives of pyrazolo [3,4-d] pyrimidine and pyrrolo [2,3-d] pyrimidine and uses thereof |
KR20060021905A (ko) | 2003-06-20 | 2006-03-08 | 셀테크 알앤디 리미티드 | 키나아제 억제제로서의 티에노피리돈 유도체 |
WO2005010008A1 (en) | 2003-07-24 | 2005-02-03 | Bayer Pharmaceuticals Corporation | Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders |
US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
EP1703902B1 (en) * | 2004-01-05 | 2010-11-03 | Merz Pharma GmbH & Co. KGaA | Memantine for the treatment of mild-to-moderate alzheimer's disease |
US20050165029A1 (en) | 2004-01-13 | 2005-07-28 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
WO2005080377A1 (ja) | 2004-02-20 | 2005-09-01 | Kirin Beer Kabushiki Kaisha | TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物 |
GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
WO2006014325A2 (en) | 2004-07-02 | 2006-02-09 | Exelixis, Inc. | C-met modulators and method of use |
EP1746099A1 (en) * | 2004-12-23 | 2007-01-24 | DeveloGen Aktiengesellschaft | Mnk1 or Mnk2 inhibitors |
JP5328342B2 (ja) | 2005-03-08 | 2013-10-30 | ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング | Mnk−1タンパク質およびMnk−2タンパク質の結晶学的構造 |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
ES2623221T3 (es) | 2005-05-20 | 2017-07-10 | Methylgene Inc | Inhibidores de la señalización del receptor de VEGF y del receptor de HGF |
WO2006136402A1 (en) | 2005-06-22 | 2006-12-28 | Develogen Aktiengesellschaft | Thienopyrimidines for pharmaceutical compositions |
US20070213305A1 (en) | 2005-11-02 | 2007-09-13 | Cytovia, Inc. | N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US20070099877A1 (en) * | 2005-11-02 | 2007-05-03 | Cytovia, Inc. | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2007059905A2 (en) | 2005-11-25 | 2007-05-31 | Develogen Aktiengesellschaft | Thienopyrimidines treating inflammatory diseases |
WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
CN1990479A (zh) | 2005-12-29 | 2007-07-04 | 中国科学院上海药物研究所 | 3-烷氧取代-2,5,7-三取代苯并吡喃-4-酮类化合物及其制备方法和包含该类化合物的药物组合物 |
US20080108611A1 (en) | 2006-01-19 | 2008-05-08 | Battista Kathleen A | Substituted thienopyrimidine kinase inhibitors |
JP5302883B2 (ja) * | 2006-04-07 | 2013-10-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬組成物用のmnk1/mnk2阻害活性を有するチエノピリミジン |
ATE456565T1 (de) | 2006-06-22 | 2010-02-15 | Biovitrum Ab Publ | Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren |
EP1889847A1 (en) | 2006-07-10 | 2008-02-20 | DeveloGen Aktiengesellschaft | Pyrrolopyrimidines for pharmaceutical compositions |
EP2219649A2 (en) | 2007-11-22 | 2010-08-25 | Boehringer Ingelheim International Gmbh | Use of mnk inhibitors for the treatment of alzheimer's disease |
EP2458912B1 (en) * | 2008-01-25 | 2014-06-04 | Huawei Technologies Co., Ltd. | Method and mobile station apparatus transmitting uplink data |
US20100015708A1 (en) * | 2008-06-18 | 2010-01-21 | Mdrna, Inc. | Ribonucleic acids with non-standard bases and uses thereof |
UY32072A (es) * | 2008-08-26 | 2010-03-26 | Boehringer Ingelheim Int | Tienopirimidinas para composiciones farmacéuticas |
US8853193B2 (en) | 2010-02-26 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions |
EA201201191A1 (ru) | 2010-02-26 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций |
WO2011104338A1 (en) | 2010-02-26 | 2011-09-01 | Boehringer Ingelheim International Gmbh | Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
UY33241A (es) | 2010-02-26 | 2011-09-30 | Boehringer Ingelheim Int | ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?. |
DK2567807T3 (en) * | 2011-09-07 | 2016-08-22 | Nordex Energy Gmbh | A process for producing a rotor blade-construction part for a wind power plant and of a previously prepared headband |
-
2006
- 2006-07-10 EP EP06014297A patent/EP1889847A1/en not_active Withdrawn
-
2007
- 2007-07-10 WO PCT/EP2007/006109 patent/WO2008006547A2/en active Application Filing
- 2007-07-10 MX MX2009000333A patent/MX2009000333A/es not_active Application Discontinuation
- 2007-07-10 AT AT07785972T patent/ATE526331T1/de not_active IP Right Cessation
- 2007-07-10 EP EP07785972A patent/EP2041137B1/en active Active
- 2007-07-10 KR KR1020097002707A patent/KR20090039757A/ko not_active Application Discontinuation
- 2007-07-10 CA CA2690277A patent/CA2690277A1/en not_active Abandoned
- 2007-07-10 BR BRPI0712882-7A patent/BRPI0712882A2/pt not_active IP Right Cessation
- 2007-07-10 JP JP2009518781A patent/JP5331951B2/ja not_active Expired - Fee Related
- 2007-07-10 US US12/373,224 patent/US8697713B2/en active Active
- 2007-07-10 EA EA200900136A patent/EA200900136A1/ru unknown
- 2007-07-10 CN CNA2007800335380A patent/CN101511837A/zh active Pending
- 2007-07-10 AU AU2007271928A patent/AU2007271928A1/en not_active Abandoned
-
2008
- 2008-12-22 ZA ZA200810785A patent/ZA200810785B/xx unknown
-
2009
- 2009-01-05 NO NO20090029A patent/NO20090029L/no not_active Application Discontinuation
- 2009-01-08 IL IL196391A patent/IL196391A0/en unknown
- 2009-01-08 CO CO09001490A patent/CO6150162A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN101511837A (zh) | 2009-08-19 |
EP2041137A2 (en) | 2009-04-01 |
NO20090029L (no) | 2009-01-28 |
WO2008006547A2 (en) | 2008-01-17 |
JP2009542749A (ja) | 2009-12-03 |
IL196391A0 (en) | 2009-09-22 |
US8697713B2 (en) | 2014-04-15 |
CA2690277A1 (en) | 2008-01-17 |
US20100105708A1 (en) | 2010-04-29 |
EA200900136A1 (ru) | 2009-06-30 |
ZA200810785B (en) | 2009-10-28 |
ATE526331T1 (de) | 2011-10-15 |
CO6150162A2 (es) | 2010-04-20 |
AU2007271928A1 (en) | 2008-01-17 |
EP1889847A1 (en) | 2008-02-20 |
EP2041137B1 (en) | 2011-09-28 |
BRPI0712882A2 (pt) | 2012-10-09 |
JP5331951B2 (ja) | 2013-10-30 |
KR20090039757A (ko) | 2009-04-22 |
WO2008006547A3 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009000333A (es) | Pirrilopirimidinas para composiciones farmaceuticas. | |
WO2006066937A3 (en) | Mnk1 or mnk2 inhibitors | |
EA200802118A1 (ru) | Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях | |
UY32072A (es) | Tienopirimidinas para composiciones farmacéuticas | |
SG179120A1 (en) | Novel compounds | |
UY33246A (es) | Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas | |
GB0625648D0 (en) | Compounds | |
EA200900983A1 (ru) | Соединения и композиции в качестве ингибиторов киназы | |
TNSN08444A1 (en) | Bicyclic derivatives as cetp inhibitors | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
TW200728305A (en) | Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease | |
WO2007058602A3 (en) | Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia. | |
WO2007115620A3 (de) | Neuartige cyclobutyl-verbindungen als kinase-inhibitoren | |
GEP20135785B (en) | Pyrrolopyrimidine compounds as cdk inhibitors | |
WO2008030412A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
SG170828A1 (en) | Deazapurines useful as inhibitors of janus kinases | |
UA94944C2 (ru) | 2,4-диаминопиримидины как ингибиторы киназ, которые принимают участие в регуляции клеточного цикла | |
TN2012000081A1 (en) | Compounds and compositions as protein kinase inhibitors | |
AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
TW200722081A (en) | New therapeutic combinations for the treatment or prevention of depression | |
EP2091328A4 (en) | SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE | |
TW200730506A (en) | Compounds and uses thereof | |
DE502005010342D1 (en) | Substituierte cyclohexylessigsäure-derivate | |
WO2007120760A3 (en) | Thiophene-carboxamides useful as inhibitors of protein kinases | |
MX2009013353A (es) | Compuestos activadores de telomerasa y metodos para su uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |